Further evidence from experiments with a KRAS G12C inhibition sensitive NSCLC cell line (NCI‐H358) showed that the combination treatment comprising AMG510 and IN10018 can induce more substantial decrease in YAP activity than either monotherapy. The gene discussed is KRAS; the disease is non-small cell lung carcinoma.